ArticleChemical & biomedical imaging2025
Mitochondrial Unfolded Protein Responsive Imaging and Surgical Navigation in Ovarian Cancer.
Article in Chemical & biomedical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unfolded proteins, as critical biomarkers in cancer, hold significant potential for tumor-specific imaging. However, the content of unfolded proteins within distinct subcellular organelles varies markedly and reflects divergent physiological implications. Currently, few fluorescent probes enable precise quantification and imaging of mitochondrial unfolded proteins. Herein, we report a fluorescent probe, MAP, for accurate imaging of mitochondrial unfolded proteins. MAP incorporates a triphenylphosphonium group that specifically targets mitochondria, with cellular uptake efficiency proportional to mitochondrial membrane potential. Within mitochondria, the maleimide moiety of MAP covalently reacts with thiol groups on unfolded proteins, restricting molecular rotation and suppressing intramolecular charge transfer (ICT), thereby triggering a significant fluorescence enhancement. Owing to the hyperpolarized mitochondrial membrane potential and abundant mitochondrial unfolded proteins in SKOV3 cells, MAP with superior biocompatibility achieves tumor-specific imaging with a high signal-to-noise ratio (9.5), enabling precise intraoperative navigation for ovarian cancer resection. This molecular design strategy provides a foundational framework for developing organelle-specific unfolded protein probes and advancing image-guided surgical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.